Please note the late-breaking abstract submission period runs from 4 to 18 January 2023. 



The late-breaking abstract submission for ESTRO 2023 is open now. The submission deadline is 18 January 2023 (23.59 HRS CET). Abstracts must be submitted online on the ESTRO website at 

We highly recommend completing your submission early, otherwise authors may experience technical delays due to server overload. 

For questions regarding the online submission process, please e-mail us at   



  • The work and/or update must be novel, ground-breaking, of high significance, evidence-based and with scientific merit. 
  • The work and/or update must be original and not previously published or presented at any other scientific meeting. 
  • The abstract must present timely findings which were not available at the time of the regular abstract submission deadline (26 October 2022). The late-breaking abstract deadline is not intended to be a second deadline for abstract submissions 
  • A limited number of late-breaking abstracts will be accepted. 
  • Submissions will be accepted for oral presentation only. 



With the submission of a late-breaking abstract for ESTRO 2023, the submitting (presenting) author: 

  • Accepts responsibility for the accuracy of the abstract and confirms that all authors are aware of the content before submission 
  • Accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about its status 
  • Accepts to declare any financial interest in products or processes described in the abstract. This includes stock ownership, membership on any advisory boards, commercially-sponsored research or any other substantial relationships 
  • Certifies that the information reported is for exclusive presentation in the session to which the abstract will be assigned if accepted, and that the information will not be presented as such at any commercially-sponsored satellite symposia during the conference. 


Further notes: 
  • Abstracts are embargoed until 1 month prior to the congress, at which point the abstract book is published online and abstracts are included in the searchable programme. Should you wish for an abstract to be embargoed until the congress, please email by 28 February 2023. 
  • Please log in to the abstract submission site with the presenting author login details. 
  • Abstracts must be submitted and presented at the conference in English. The Scientific Programme Committee reserves the right to reject an abstract written in poor English. 



All late-breaking abstracts are submitted under the Clinical track are reviewed by clinicians and considered for the Clinical track of ESTRO 2023 only. 

Further Advice for Submitters

Keywords - Authors are required to list a keyword of their choice that best fits the content of the abstract. 

Title - Abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is important since it focuses attention (it is the “showcase” for the presentation). Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations. Prospective clinical trials should be identified as such in the title of the abstract (include The National Clinical Trial number when applicable) 

Body of the abstract - Abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/Methods; (3) Results; (4) Conclusion. 

The online abstract submission procedure - The online abstract submission system will not accept abstracts that exceed 3,000 characters (body of the abstract, including spaces). 

Abbreviations - The use of standard abbreviations is desirable. A special or unusual abbreviation must be placed (in round brackets) after the first appearance of the word for which it stands. 

Table and image - With their submission, authors may include a maximum of 2 uploads (tables or images) in JPG or PNG formats. These uploads are not included in the number of allotted characters. The maximum pixel size of an image is 600(w) x 800 (h). 

Data table - Authors may include one data table using the insert table icon (we advise not to copy-paste a table into the body of the abstract). The characters in a data table are included in the overall number of characters allowed. 

Equations - Can be inserted in the text as images. 

Editing of abstracts - Abstracts can be edited until the submission deadline of 18 January 2023. Any changes to abstracts (including authors and affiliations) are not accepted after this date. 



Abstracts submitted for presentation will be reviewed by the Scientific Programme Committee. 

Abstract review criteria are based on the late-breaking nature of the abstract, clarity, supporting data, scientific rigour, potential significance, interest in the topic chosen and innovation or usefulness. 

  • Work in progress: abstracts on research obviously not yet performed and results not yet obtained will be rejected.   
  • Case studies will not be considered (only if first in human)  
  • Encore abstracts: papers already presented in another meeting will not be considered, unless the previous audience is distinct from the ESTRO 2023 congress audience (e.g. national meetings).   
  • Abstracts should include new information and not solely include materials already published.  
  • If very similar abstracts are submitted by the same authors, the Scientific Programme Committee reserves the right to select only one of the abstracts and reject any others.  


Notification of the outcome of abstract selection will be sent by mid-February 2023.  

Please note that acceptance of an abstract does not entitle the authors to a complimentary registration. Presenting authors should register for the congress by mid-February 2023.